000 | 03034nam a22005295i 4500 | ||
---|---|---|---|
001 | 978-3-319-78238-6 | ||
003 | DE-He213 | ||
005 | 20210201191423.0 | ||
007 | cr nn 008mamaa | ||
008 | 180424s2018 gw | s |||| 0|eng d | ||
020 |
_a9783319782386 _9978-3-319-78238-6 |
||
050 | 4 | _aRC261-271 | |
072 | 7 |
_aMJCL _2bicssc |
|
072 | 7 |
_aMED062000 _2bisacsh |
|
072 | 7 |
_aMJCL _2thema |
|
082 | 0 | 4 |
_a614.5999 _223 |
245 | 1 | 0 |
_aResistance to Ibritumomab in Lymphoma _h[electronic resource] / _cedited by Makoto Hosono, Jean-François Chatal. |
250 | _a1st ed. 2018. | ||
264 | 1 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2018. |
|
300 |
_aXIII, 158 p. 18 illus., 14 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 |
_aResistance to Targeted Anti-Cancer Therapeutics, _x2196-5501 ; _v18 |
|
500 | _aAcceso multiusuario | ||
505 | 0 | _aClinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index. | |
520 | _aThis volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab. | ||
541 |
_fUABC ; _cTemporal ; _d01/01/2021-12/31/2023. |
||
650 | 0 | _aCancer research. | |
650 | 1 | 4 |
_aCancer Research. _0https://scigraph.springernature.com/ontologies/product-market-codes/B11001 |
700 | 1 |
_aHosono, Makoto. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
700 | 1 |
_aChatal, Jean-François. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer Nature eBook | |
776 | 0 | 8 |
_iPrinted edition: _z9783319782379 |
776 | 0 | 8 |
_iPrinted edition: _z9783319782393 |
776 | 0 | 8 |
_iPrinted edition: _z9783030086527 |
830 | 0 |
_aResistance to Targeted Anti-Cancer Therapeutics, _x2196-5501 ; _v18 |
|
856 | 4 | 0 |
_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-78238-6 |
912 | _aZDB-2-SBL | ||
912 | _aZDB-2-SXB | ||
942 | _cLIBRO_ELEC | ||
999 |
_c243288 _d243287 |